Compugen (CGEN) saw its loss widen to $8.71 million, or $0.17 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $8.60 million, or $0.17 a share.
The company has not recorded any revenues for the current quarter. However, it has reported a revenue of $0.09 million for the previous year period.
Operating loss for the quarter was $8.78 million, compared with an operating loss of $8.87 million in the previous year period.
Anat Cohen-Dayag, Ph.D., chief executive officer and president of Compugen, stated, "During this quarter we saw continuing scientific and therapeutic development advancements as well as business development progress in our four focus program areas."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]